Circulating Monocyte Chemoattractant Protein-1 in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction Treated with Mild Hypothermia: A Biomarker Substudy of SHOCK-COOL Trial

Background: There is evidence that monocyte chemoattractant protein-1 (MCP-1) levels reflect the intensity of the inflammatory response in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI) and have a predictive value for clinical outcomes. However, little is known about the effect of mild therapeutic hypothermia (MTH) on the inflammatory response in patients with CS complicating AMI. Therefore, we conducted a biomarker study to investigate the effect of MTH on MCP-1 levels in patients with CS complicating AMI. Methods: In the randomized mild hypothermia in cardiogenic shock (SHOCK-COOL) trial, 40 patients with CS complicating AMI were enrolled and assigned to MTH (33 °C) for 24 h or normothermia at a 1:1 ratio. Blood samples were collected at predefined time points at the day of admission/day 1, day 2 and day 3. Differences in MCP-1 levels between and within the MTH and normothermia groups were assessed. Additionally, the association of MCP-1 levels with the risk of all-cause mortality at 30 days was analyzed. Missing data were accounted for by multiple imputation as sensitivity analyses. Results: There were differences in MCP-1 levels over time between patients in MTH and normothermia groups (P for interaction = 0.013). MCP-1 levels on day 3 were higher than on day 1 in the MTH group (day 1 vs day 3: 21.2 [interquartile range, 0.25–79.9] vs. 125.7 [interquartile range, 87.3–165.4] pg/mL; p = 0.006) and higher than in the normothermia group at day 3 (MTH 125.7 [interquartile range, 87.3–165.4] vs. normothermia 12.3 [interquartile range, 0–63.9] pg/mL; p = 0.011). Irrespective of therapy, patients with higher levels of MCP-1 at hospitalization tended to have a decreased risk of all-cause mortality at 30 days (HR, 2.61; 95% CI 0.997–6.83; p = 0.051). Conclusions: The cooling phase of MTH had no significant effect on MCP-1 levels in patients with CS complicating AMI compared to normothermic control, whereas MCP-1 levels significantly increased after rewarming. Trial registration: NCT01890317.

[1]  Sunil V. Rao,et al.  Cardiogenic Shock After Acute Myocardial Infarction: A Review. , 2021, JAMA.

[2]  N. Frangogiannis,et al.  Chemokines in Myocardial Infarction , 2020, Journal of Cardiovascular Translational Research.

[3]  J. Chao,et al.  MCP-1 mediates ischemia/reperfusion-induced cardiomyocyte apoptosis via MCPIP1 and CaSR. , 2019, American journal of physiology. Heart and circulatory physiology.

[4]  E. Ohman,et al.  Management of cardiogenic shock complicating myocardial infarction: an update 2019. , 2019, European heart journal.

[5]  G. Schuler,et al.  Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction: Randomized SHOCK-COOL Trial , 2019, Circulation.

[6]  C. Haiman,et al.  Association of Coffee Consumption With Total and Cause-Specific Mortality Among Nonwhite Populations , 2017, Annals of Internal Medicine.

[7]  R. Kloner,et al.  Therapeutic Hypothermia Reduces the Inflammatory Response Following Ischemia/Reperfusion Injury in Rat Hearts , 2016, Therapeutic hypothermia and temperature management.

[8]  G. Schuler,et al.  Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock , 2017, Clinical Research in Cardiology.

[9]  Jiaqi Liu,et al.  Inflammation and Inflammatory Cells in Myocardial Infarction and Reperfusion Injury: A Double-Edged Sword , 2016, Clinical Medicine Insights. Cardiology.

[10]  G. Schuler,et al.  Prognostic impact of established and novel renal function biomarkers in myocardial infarction with cardiogenic shock: A biomarker substudy of the IABP-SHOCK II-trial. , 2015, International journal of cardiology.

[11]  M. Neri,et al.  Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. , 2015, Current vascular pharmacology.

[12]  G. Schuler,et al.  Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial , 2014, Critical Care.

[13]  J. G. van der Hoeven,et al.  Seventy-two hours of mild hypothermia after cardiac arrest is associated with a lowered inflammatory response during rewarming in a prospective observational study , 2014, Critical Care.

[14]  G. Schuler,et al.  Growth‐differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP‐SHOCK II‐trial , 2014, European journal of heart failure.

[15]  J. Horn,et al.  Cardiac arrest patients have an impaired immune response, which is not influenced by induced hypothermia , 2014, Critical Care.

[16]  Irene Riezzo,et al.  A theoretical timeline for myocardial infarction: immunohistochemical evaluation and western blot quantification for Interleukin-15 and Monocyte chemotactic protein-1 as very early markers , 2014, Journal of Translational Medicine.

[17]  D. Kolte,et al.  Trends in Incidence, Management, and Outcomes of Cardiogenic Shock Complicating ST‐Elevation Myocardial Infarction in the United States , 2014, Journal of the American Heart Association.

[18]  M. Nahrendorf,et al.  Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure , 2013, Science.

[19]  J. Haerting,et al.  Acute myocardial infarction and cardiogenic shock , 2012, Medizinische Klinik - Intensivmedizin und Notfallmedizin.

[20]  J. G. van der Hoeven,et al.  Rewarming after hypothermia after cardiac arrest shifts the inflammatory balance* , 2012, Critical care medicine.

[21]  J. Haerting,et al.  Acute myocardial infarction and cardiogenic shock: prognostic impact of cytokines: INF-γ, TNF-α, MIP-1β, G-CSF, and MCP-1β. , 2012, Medizinische Klinik, Intensivmedizin und Notfallmedizin.

[22]  D. Erlinge,et al.  Hypothermia in cardiogenic shock reduces systemic t-PA release , 2011, Journal of Thrombosis and Thrombolysis.

[23]  M. Pittet,et al.  Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. , 2010, Circulation.

[24]  J. Scholz,et al.  Hypothermia and Postconditioning after Cardiopulmonary Resuscitation Reduce Cardiac Dysfunction by Modulating Inflammation, Apoptosis and Remodeling , 2009, PloS one.

[25]  P. Kolattukudy,et al.  Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. , 2009, Clinical science.

[26]  A. Diestel,et al.  Hypothermia downregulates inflammation but enhances IL-6 secretion by stimulated endothelial cells. , 2008, Cryobiology.

[27]  H. Christensen,et al.  Comparison of data analysis strategies for intent-to-treat analysis in pre-test–post-test designs with substantial dropout rates , 2008, Psychiatry Research.

[28]  Masafumi Takahashi,et al.  MCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen species. , 2008, Cardiovascular research.

[29]  N. Frangogiannis.  The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes. , 2007, Journal of the American College of Cardiology.

[30]  R. Califf,et al.  Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. , 2007, Journal of the American College of Cardiology.

[31]  Ying Xia,et al.  MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. , 2007, Inflammation & allergy drug targets.

[32]  T. Vanden Hoek,et al.  Hypothermia-induced cardioprotection using extended ischemia and early reperfusion cooling. , 2007, American journal of physiology. Heart and circulatory physiology.

[33]  Mahua Choudhury,et al.  Monocyte Chemoattractant Protein-1 Induces a Novel Transcription Factor That Causes Cardiac Myocyte Apoptosis and Ventricular Dysfunction , 2006, Circulation research.

[34]  J. Berman,et al.  MCP-1/CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a G(alphai)-independent pathway. , 2005, Biochemical and biophysical research communications.

[35]  Craig K. Enders,et al.  Using the SPSS Mixed Procedure to Fit Cross-Sectional and Longitudinal Multilevel Models , 2005 .

[36]  P. Giannoudis,et al.  Effects of hypothermia and re-warming on the inflammatory response in a murine multiple hit model of trauma. , 2005, Cytokine.

[37]  A. Khera,et al.  Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. , 2004, Journal of the American College of Cardiology.

[38]  D. Mann,et al.  Duality of innate stress responses in cardiac injury, repair, and remodeling. , 2004, Journal of molecular and cellular cardiology.

[39]  H. Kubo,et al.  Effects of rewarming on nuclear factor-&kgr;B and interleukin 8 expression in cold-preserved alveolar epithelial cells , 2003, Transplantation.

[40]  P. Vaagenes,et al.  Rapid rewarming after mild hypothermia accentuates the inflammatory response after acute volume controlled haemorrhage in spontaneously breathing rats. , 2003, Resuscitation.

[41]  E. Antman,et al.  Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.

[42]  W. Schaper,et al.  Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice mimics ischemic preconditioning through SAPK/JNK1/2 activation. , 2003, Cardiovascular research.

[43]  J. Berman,et al.  Chemokine expression in myocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomyocytes from cell death. , 2002, Journal of molecular and cellular cardiology.

[44]  B. Rollins,et al.  Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[45]  C. Orosz,et al.  Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. , 1998, The American journal of pathology.